Loss-of-function genetic screens as a tool to improve the diagnosis and treatment of cancer.

A major impediment to the effective treatment of cancer is the molecular heterogeneity of the disease, which is also reflected in an equally diverse pattern of clinical responses to therapy. Currently, only few drugs are available that can be used safely and effectively to treat cancer. To improve this situation, the development of novel and highly specific targets for therapy is of utmost importance. Possibly even more importantly, we need better tools to predict which patients will respond to specific therapies. Such drug response biomarkers will be instrumental to individualize the therapy of patients having seemingly similar cancers. In this study, we discuss how RNA interference-based genetic screens can be used to address these two pressing needs in the care for cancer patients.
AuthorsJ Mullenders, R Bernards
JournalOncogene (Oncogene) Vol. 28 Issue 50 Pg. 4409-20 (Dec 17 2009) ISSN: 1476-5594 [Electronic] England
PMID19767776 (Publication Type: Journal Article, Review)
Chemical References
  • Biomarkers, Tumor
  • RNA, Small Interfering
  • Animals
  • Biomarkers, Tumor
  • Drug Resistance, Neoplasm
  • Genetic Testing
  • Humans
  • Neoplasms (diagnosis, drug therapy, genetics)
  • Phenotype
  • RNA Interference
  • RNA, Small Interfering (genetics)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!

Choose Username:
Verify Password: